GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Shiller PE Ratio

Corcept Therapeutics (Corcept Therapeutics) Shiller PE Ratio : 34.55 (As of Apr. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Shiller PE Ratio?

As of today (2024-04-28), Corcept Therapeutics's current share price is $22.80. Corcept Therapeutics's E10 for the quarter that ended in Dec. 2023 was $0.66. Corcept Therapeutics's Shiller PE Ratio for today is 34.55.

The historical rank and industry rank for Corcept Therapeutics's Shiller PE Ratio or its related term are showing as below:

CORT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 32.7   Med: 68.55   Max: 679.5
Current: 34.68

During the past years, Corcept Therapeutics's highest Shiller PE Ratio was 679.50. The lowest was 32.70. And the median was 68.55.

CORT's Shiller PE Ratio is ranked worse than
50.68% of 146 companies
in the Biotechnology industry
Industry Median: 34.31 vs CORT: 34.68

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Corcept Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.280. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.66 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Corcept Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Shiller PE Ratio Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 486.38 162.88 62.68 42.18 49.41

Corcept Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.18 41.65 39.22 44.24 49.41

Competitive Comparison of Corcept Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Corcept Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Shiller PE Ratio falls into.



Corcept Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Corcept Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=22.80/0.66
=34.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Corcept Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.28/129.4194*129.4194
=0.280

Current CPI (Dec. 2023) = 129.4194.

Corcept Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.140 99.695 -0.182
201406 -0.070 100.560 -0.090
201409 -0.060 100.428 -0.077
201412 -0.040 99.070 -0.052
201503 -0.050 99.621 -0.065
201506 -0.020 100.684 -0.026
201509 -0.010 100.392 -0.013
201512 0.010 99.792 0.013
201603 0.000 100.470 0.000
201606 0.010 101.688 0.013
201609 0.020 101.861 0.025
201612 0.040 101.863 0.051
201703 0.040 102.862 0.050
201706 0.100 103.349 0.125
201709 0.110 104.136 0.137
201712 0.770 104.011 0.958
201803 0.140 105.290 0.172
201806 0.140 106.317 0.170
201809 0.140 106.507 0.170
201812 0.180 105.998 0.220
201903 0.150 107.251 0.181
201906 0.170 108.070 0.204
201909 0.220 108.329 0.263
201912 0.240 108.420 0.286
202003 0.250 108.902 0.297
202006 0.230 108.767 0.274
202009 0.170 109.815 0.200
202012 0.200 109.897 0.236
202103 0.180 111.754 0.208
202106 0.210 114.631 0.237
202109 0.240 115.734 0.268
202112 0.260 117.630 0.286
202203 0.200 121.301 0.213
202206 0.240 125.017 0.248
202209 0.300 125.227 0.310
202212 0.140 125.222 0.145
202303 0.140 127.348 0.142
202306 0.250 128.729 0.251
202309 0.280 129.860 0.279
202312 0.280 129.419 0.280

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (NAS:CORT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Corcept Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025